Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBM Accounting: Express Scripts Says Retail Rx Copays Are Not Revenue

Executive Summary

Express Scripts is urging the Securities & Exchange Commission to avoid setting PBM accounting standards that require companies to count patients' retail pharmacy copayments as revenue

You may also be interested in...



AdvancePCS copay revenue

AdvancePCS' revenue and cost of revenue would each increase "15-25%" for FY 2003 if SEC requires reporting of copays to clients as revenue, CEO David Halbert says. FY 2002 revenue without copays totaled $3.4 bil.; that number could grow as large as $4.3 bil. with addition of copay revenue. PBMs are preparing for a Securities & Exchange Commission decision on a uniform standard for copay accounting (1"The Pink Sheet" March 31, p. 26)...

AdvancePCS copay revenue

AdvancePCS' revenue and cost of revenue would each increase "15-25%" for FY 2003 if SEC requires reporting of copays to clients as revenue, CEO David Halbert says. FY 2002 revenue without copays totaled $3.4 bil.; that number could grow as large as $4.3 bil. with addition of copay revenue. PBMs are preparing for a Securities & Exchange Commission decision on a uniform standard for copay accounting (1"The Pink Sheet" March 31, p. 26)...

Express Scripts Mail-Order Rx Penetration Could Double In 5 Years, Firm Says

Express Scripts plans to push the percentage of prescriptions filled by mail-order over 35% within the next five years, Chief Financial Officer George Paz told the recent SG Cowen healthcare conference in Boston

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel